Health & Bio

Pfizer BRAFTOVI colon cancer 64% response rate

BREAKWATER phase 3 Cohort 3: BRAFTOVI+cetuximab+FOLFIRI in BRAF V600E metastatic colorectal cancer achieved 64% ORR.

Primary sources · 1
Pfizer
← View the full 2026-05-14 (Thu) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →